Druz, Guinot To Have Key Roles in California-Based Pharmaceutical Company

PALO ALTO, Calif. – Feb. 2, 2001 – Pharmagenesis, Inc. has elevated Nicolas Druz to chairman and CEO.  Francois Guinot, board member and managing director of BioMérieux-Pierre Fabre, the leading French private pharmaceutical and cosmetics company, has been named president.

As president, Guinot will supervise scientific and business development progress for Pharmagenesis, including licensing strategy and negotiation, as well as handling business development for the company’s line of pharmaceuticals.  In addition to his roles at Pharmagenesis and BioMérieux Pierre Fabre, Guinot is director at Transgene, a French biopharmaceutical company dedicated to the discovery and development of gene delivery technologies and gene therapy.  Guinot also served as CEO of Rhône Poulenc Santé and chairman and CEO of Rhône Poulenc Chimie.

“Guinot’s background in drug development and international business ventures complements the experience of our management team,” said Druz.  “His operations background and extensive distribution contacts will be an enormous asset as we plan the introduction of our new pharmaceuticals to markets in North America, Europe and Asia.”

Druz oversees product development, marketing and operations for the product-driven biotechnology group.  He has been with the company for five years, representing the interests of the Wang family, Pharmagenesis’ reference shareholder.

Druz also serves as chairman and CEO of Orchid, a Luxembourg-based financial holding company. In addition to his work with Pharmagenesis, Druz is vice chairman of Harmonie SA, director of Clinique de Paris, managing director of Auriga, vice chairman of Tianjin Hualong Pharmaceutical and a board member of Phytohealth.  He is also president and CEO of Europe Journal, president and CEO of Euro Pacific Communication and a board member of Société des Papiers de Presse.

Pharmagenesis, Inc.

Pharmagenesis, Inc. develops ethical pharmaceuticals from purified extracts of plants that have been employed in traditional Chinese medicine for more than 4,000 years.  The efficacy will be validated by clinical trials conforming to standards of appropriate government regulatory agencies.  The company is currently focused on developing anticancer therapies, treatments for cancer therapy-related bone-marrow suppression and for the management of transplant rejection.  These pharmaceuticals will be commercialized initially in the high-growth markets of China and Taiwan.

Pharmagenesis' corporate headquarters, where the company also has an R & D facility employing cutting-edge Western medical research techniques, is based in Palo Alto, Calif.  A privately-held company, Pharmagenesis also has operations in Beijing and Taipei.


May 22, 2001 ] April 2, 2001 ] April 16, 2001 ] Mar 19, 2001 ] Feb 23, 2001 ] [ Feb 2, 2001 ] Dec, 2000 ]

Home ] SAB ] Milestones ] Business Dev ] Press Releases ]